10.23.13
Manja Bouman, Ph.D., has been appointed president and business unit director of DSM Pharmaceutical Products biopharm businesses. Dr. Bouman will head the DSM Biologics and BioSolutions businesses and will serve on the management team. Dr. Bouman reports to Lukas Utiger, president and chief executive officer of DSM Pharmaceutical Products.
Dr. Bouman most recently served as chief executive officer of Regenesance B.V. In 2004, she served as chief executive officer of Kiadis Pharma B.V. Dr. Bouman joined DSM Gist-Brocades in 1997 and was responsible for new business development and licensing and technology.
DSM Biologics has operations in Groningen, The Netherlands and in Brisbane, Australia, and specializes in preclinical through commercial biomanufacturing of recombinant proteins and monoclonal antibodies based on mammalian cell cultures. Dr. Bouman also heads DSM BioSolutions, which offers large-scale fermentation for large and small molecule active pharmaceutical ingredients for therapeutic proteins and enzymes at DSM’s Capua, Italy site, with support from the DSM Biotechnology Center in Delft, The Netherlands.
Dr. Bouman most recently served as chief executive officer of Regenesance B.V. In 2004, she served as chief executive officer of Kiadis Pharma B.V. Dr. Bouman joined DSM Gist-Brocades in 1997 and was responsible for new business development and licensing and technology.
DSM Biologics has operations in Groningen, The Netherlands and in Brisbane, Australia, and specializes in preclinical through commercial biomanufacturing of recombinant proteins and monoclonal antibodies based on mammalian cell cultures. Dr. Bouman also heads DSM BioSolutions, which offers large-scale fermentation for large and small molecule active pharmaceutical ingredients for therapeutic proteins and enzymes at DSM’s Capua, Italy site, with support from the DSM Biotechnology Center in Delft, The Netherlands.